Volume 25, Issue 8, Pages (August 2017)

Slides:



Advertisements
Similar presentations
Volume 5, Issue 6, Pages (June 2002)
Advertisements

Volume 8, Issue 2, Pages (August 2003)
Sp1 Suppresses miR-3178 to Promote the Metastasis Invasion Cascade via Upregulation of TRIOBP  Hui Wang, Kai Li, Yu Mei, Xuemei Huang, Zhenglin Li, Qingzhu.
Volume 19, Issue 3, Pages (March 2017)
Development of Cell-Penetrating Asymmetric Interfering RNA Targeting Connective Tissue Growth Factor  Jihye Hwang, Chanil Chang, Ji Hyun Kim, Chang Taek.
Volume 5, Issue 4, Pages (April 2004)
Type I IL-1 Receptor Mediates IL-1 and Intracellular IL-1 Receptor Antagonist Effects in Skin Inflammation  Gaby Palmer, Dominique Talabot-Ayer, Gürkan.
Roger B. Deal, Steven Henikoff  Developmental Cell 
Identification of Paracaspases and Metacaspases
Volume 8, Issue 4, Pages (April 2015)
Molecular Therapy - Methods & Clinical Development
Hermann Broder Schmidt, Rajat Rohatgi  Cell Reports 
Volume 91, Issue 3, Pages (August 2016)
Human Senataxin Resolves RNA/DNA Hybrids Formed at Transcriptional Pause Sites to Promote Xrn2-Dependent Termination  Konstantina Skourti-Stathaki, Nicholas J.
Volume 25, Issue 6, Pages (June 2017)
Volume 4, Issue 1, Pages (July 1999)
Single Amino Acid Deletion in Kindlin-1 Results in Partial Protein Degradation Which Can Be Rescued by Chaperone Treatment  Kristin Maier, Yinghong He,
Volume 15, Issue 22, Pages (November 2005)
Sherilyn Grill, Valerie M. Tesmer, Jayakrishnan Nandakumar 
Volume 25, Issue 9, Pages (September 2017)
Volume 45, Issue 5, Pages (March 2012)
Volume 13, Issue 10, Pages (December 2015)
The extent of degeneration of cruciate ligament is associated with chondrogenic differentiation in patients with osteoarthritis of the knee  K. Kumagai,
Volume 154, Issue 1, Pages (July 2013)
Volume 16, Issue 12, Pages (June 2006)
M.Brandon Parrott, Michael A. Barry  Molecular Therapy 
Volume 22, Issue 6, Pages (February 2018)
Volume 4, Issue 6, Pages (December 2001)
Volume 25, Issue 3, Pages (March 2017)
Molecular Therapy - Nucleic Acids
Figure 3. MAb 19H9 displays broad cross-reactivity with IAV strains of different subtypes. (A), Amino acid sequence ... Figure 3. MAb 19H9 displays broad.
Jungmook Lyu, Vicky Yamamoto, Wange Lu  Developmental Cell 
Volume 14, Issue 1, Pages (July 2011)
Volume 22, Issue 20, Pages (October 2012)
Volume 5, Issue 6, Pages (June 2002)
Spatially and Temporally Regulated NRF2 Gene Therapy Using Mcp-1 Promoter in Retinal Ganglion Cell Injury  Kosuke Fujita, Koji M. Nishiguchi, Yukihiro.
Volume 23, Issue 8, Pages (May 2018)
Molecular Therapy - Methods & Clinical Development
Lizhong Xu, Veronica Lubkov, Laura J. Taylor, Dafna Bar-Sagi 
Kentaro Abe, Masatoshi Takeichi  Neuron 
Bo Li, Ran-Sook Woo, Lin Mei, Roberto Malinow  Neuron 
Volume 22, Issue 6, Pages (February 2018)
Inclusion of jaagsiekte sheep retrovirus proviral elements markedly increases lentivirus vector pseudotyping efficiency  Patrick L. Sinn, Erin R. Burnight,
Volume 23, Issue 2, Pages (February 2015)
EphB/Syndecan-2 Signaling in Dendritic Spine Morphogenesis
Volume 25, Issue 2, Pages (February 2017)
Molecular Therapy - Methods & Clinical Development
Overexpression of Fetuin-A Counteracts Ectopic Mineralization in a Mouse Model of Pseudoxanthoma Elasticum (Abcc6−/−)  Qiujie Jiang, Florian Dibra, Michael.
Volume 50, Issue 6, Pages (June 2013)
Dan Yu, Rongdiao Liu, Geng Yang, Qiang Zhou  Cell Reports 
STIL Microcephaly Mutations Interfere with APC/C-Mediated Degradation and Cause Centriole Amplification  Christian Arquint, Erich A. Nigg  Current Biology 
Volume 8, Issue 2, Pages (August 2003)
Volume 129, Issue 2, Pages (April 2007)
The histidine-rich loop regulates accessibility of the active site and RDEL motif in vivo. The histidine-rich loop regulates accessibility of the active.
Molecular Therapy - Methods & Clinical Development
Volume 26, Issue 11, Pages e5 (March 2019)
In Vitro Analysis of Huntingtin-Mediated Transcriptional Repression Reveals Multiple Transcription Factor Targets  Weiguo Zhai, Hyunkyung Jeong, Libin.
Volume 27, Issue 6, Pages e4 (May 2019)
Quan Jin, Chunping Qiao, Jianbin Li, Juan Li, Xiao Xiao 
Pervasive Targeting of Nascent Transcripts by Hfq
Volume 15, Issue 5, Pages (May 2016)
Hermann Broder Schmidt, Rajat Rohatgi  Cell Reports 
Volume 9, Issue 2, Pages (February 2004)
Volume 2, Issue 3, Pages (September 1998)
Volume 28, Issue 8, Pages e4 (August 2019)
Jörg Hartkamp, Brian Carpenter, Stefan G.E. Roberts  Molecular Cell 
Volume 23, Issue 10, Pages (June 2018)
Volume 26, Issue 4, Pages (April 2018)
Aminoglycoside Enhances the Delivery of Antisense Morpholino Oligonucleotides In Vitro and in mdx Mice  Mingxing Wang, Bo Wu, Sapana N. Shah, Peijuan.
Volume 27, Issue 9, Pages e5 (May 2019)
Presentation transcript:

Volume 25, Issue 8, Pages 1854-1865 (August 2017) Codon-Optimized RPGR Improves Stability and Efficacy of AAV8 Gene Therapy in Two Mouse Models of X-Linked Retinitis Pigmentosa  M. Dominik Fischer, Michelle E. McClements, Cristina Martinez-Fernandez de la Camara, Julia-Sophia Bellingrath, Daniyar Dauletbekov, Simon C. Ramsden, Doron G. Hickey, Alun R. Barnard, Robert E. MacLaren  Molecular Therapy  Volume 25, Issue 8, Pages 1854-1865 (August 2017) DOI: 10.1016/j.ymthe.2017.05.005 Copyright © 2017 The Authors Terms and Conditions

Figure 1 Analysis of RPGRORF15 Expression Levels Based on Wild-Type versus Codon-Optimized Plasmid Constructs (A) Western blot of whole protein lysates from transfected HEK293T cells. Untransfected cells were used as negative control (nc), which only show a positive band at 47 kDa indicating the loading control GAPDH. (B and C) Codon-optimized and wild-type plasmid transfected cells were loaded in an alternating fashion, and signal intensity of bands at 220 kDa (indicating RPGR) were quantified. (B) Boxplot (median, box delineates lower and upper quartile, whiskers minimum and maximum) of intensities in arbitrary units (AU) after normalization to the loading control (GAPDH). (C) Bar graph (mean ± SD) after normalization to wild-type levels for a fold change presentation. After confirming the normal distribution of the dataset (n = 4), significance was tested by one-tailed t test for paired samples of unequal variance. *p < 0.005. Molecular Therapy 2017 25, 1854-1865DOI: (10.1016/j.ymthe.2017.05.005) Copyright © 2017 The Authors Terms and Conditions

Figure 2 Liquid Chromatography-Tandem Mass Spectrometry of wtRPGRORF15 and coRPGRORF15 (A) Following overexpression in HEK293T cells, wtRPGRORF15 and coRPGRORF15 were purified from whole cell lysate by SDS-PAGE. In each lane, a single band above 180 kDa was identified as RPGRORF15 (arrow). This band was missing in the negative control (nc) lanes. No additional bands are visible, which would be different between WT and coRPGRORF15 lanes. (B) Identified RPGRORF15 bands were then excised for liquid chromatography-tandem mass spectrometry (LC-MS/MS) analysis. More than 80% of peptide sequence could be directly identified (indicated by dark arrows below amino acid sequence). Unidentified amino acids (no arrows) are largely based in the ORF15 sequence, which escapes LC-MS/MS analysis because of its repetitive, glutamic acid and glycine-rich sequence. Note that the C-terminal sequence following the ORF15 region was identified, which rules out premature termination of translation. Together with the identical migration pattern between the wtRPGRORF15 and coRPGRORF15 samples in the SDS-PAGE (A), this suggests that codon optimization does not result in alternative splicing, but in a protein product equivalent to the wtRPGRORF15. Molecular Therapy 2017 25, 1854-1865DOI: (10.1016/j.ymthe.2017.05.005) Copyright © 2017 The Authors Terms and Conditions

Figure 3 Western Blot Analysis of RPGR Expression and Glutamylation (A) RPGRORF15 expression (black arrowhead) was detected in HEK293T cells transfected with either coRPGRORF15 (co) or wtRPGRORF15 (wt) containing plasmids compared with untransfected samples (UNT). A truncated 80 kDa protein (white arrowhead) was detected with an N terminus-directed RPGR antibody in cells transfected with the WT plasmid compared with cells transfected with the codon-optimized plasmid. (B) Glutamylated RPGRORF15 was detected with the GT335 antibody in HEK293T cells transfected with the codon-optimized and the WT sequence of RPGRORF15. (A and B) The 80 kDa band in (A) was not glutamylated in (B) and may therefore represent a truncated RPGR variant with a C-terminal deletion. Molecular Therapy 2017 25, 1854-1865DOI: (10.1016/j.ymthe.2017.05.005) Copyright © 2017 The Authors Terms and Conditions

Figure 4 Immunohistochemical Analysis of Treated and Untreated Eyes of C57BL/6, C57BL/6Rd9/Boc, and Rpgr−/y mice Representative sections from control untreated (top panels) and AAV.coRPGRORF15-treated eyes in C57BL/6 mice were stained with Hoechst (blue) and antibodies against human RPGR (SIGMA N-terminal; green) and mouse Rpgrip1 (red). Top panels show no human RPGR expression in a control untreated eye, whereas Rpgrip1 (red) indicates location of the connecting cilia. Treatment with AAV.coRPGRORF15 resulted in RPGR expression (second row) and co-localization of human RPGR with Rpgrip1 (red). Middle panels show the same for C57BL/6Rd9/Boc mice and lower panels for Rpgr−/y mice. Scale bars, 20 μm. Molecular Therapy 2017 25, 1854-1865DOI: (10.1016/j.ymthe.2017.05.005) Copyright © 2017 The Authors Terms and Conditions

Figure 5 Electroretinographic Analysis of Treated versus Untreated Eyes of C57BL/6, Rpgr−/y, and C57BL/6Rd9/Boc Mice at 6 Months of Age Left panels indicate mean (±95% confidence interval) amplitudes of dark-adapted a- and b-wave amplitudes after single light flashes over a luminance series. Right panels show results in the light-adapted state. (A–C) Lack of toxicity in C57BL/6 mice is shown in (A), whereas sum potentials show treatment effects in both disease models Rpgr−/y (B) and C57BL/6Rd9/Boc mice (C). The most robust treatment effect can be observed between −1 and 1 log cd*s/m2 in the dark-adapted luminance series. Red represents treated eyes; black represents untreated eyes. Molecular Therapy 2017 25, 1854-1865DOI: (10.1016/j.ymthe.2017.05.005) Copyright © 2017 The Authors Terms and Conditions